CD3G

Across TCGA pan-cancer cohorts, CD3G mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CD3G data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CD3G mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD3G expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where CD3G mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.554	0.947	.003	16	view →
LUAD	DFS	Quartile	All	0.881	0.502	.001	9	view →
PDAC	DFS	Quartile	All	0.894	0.747	.016	7	view →
HNSC	DFS	Tertile	All	0.918	1.000	.020	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CD3G–LSCC (DFS)

Open the LSCC breakdown →